发明名称 |
LYOPHILIZED RECOMBINANT VWF FORMULATIONS |
摘要 |
The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. |
申请公布号 |
US2016129090(A1) |
申请公布日期 |
2016.05.12 |
申请号 |
US201514939364 |
申请日期 |
2015.11.12 |
申请人 |
BAXALTA INCORPORATED ;BAXALTA GMBH |
发明人 |
Schnecker Kurt;Haidweger Eva;Turecek Peter |
分类号 |
A61K38/36;A61K47/26;A61K47/12;A61K47/22;A61K9/19;A61K47/18 |
主分类号 |
A61K38/36 |
代理机构 |
|
代理人 |
|
主权项 |
1. A stable lyophilized pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) one or more buffering agents; (c) one or more amino acids; (d) one or more stabilizing agents; and (e) one or more surfactants;
said rVWF comprising a polypeptide selected from the group consisting of: a) the amino acid sequence set out in SEQ ID NO: 3; b) a biologically active analog, fragment or variant of a); c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1; d) a biologically active analog, fragment or variant of c); and e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions; said buffer is comprising of a pH buffering agent in a range of about 0.1 mM to about 500 mM and said pH is in a range of about 2.0 to about 12.0; said amino acid is at a concentration of about 1 to about 500 mM; said stabilizing agent is at a concentration of about 0.1 to about 1000 mM; and said surfactant is at a concentration of about 0.01 g/L to about 0.5 g/L. |
地址 |
Bannockburn IL US |